A commentary on the efficacy of olanzapine for the treatment of schizophrenia: The past, present, and future

Leslie Citrome, Joseph P. McEvoy, Mark S. Todtenkopf, David McDonnell, Peter J. Weiden

Research output: Contribution to journalReview article

Abstract

Olanzapine is a second-generation atypical antipsychotic with proven efficacy for the treatment of schizophrenia. Approved in 1996, olanzapine is one of the most studied antipsychotics, resulting in a considerable amount of clinical data across diverse patient populations. Despite the fact that olanzapine is associated with a known risk of metabolic side effects, including weight gain, many clinicians continue to prescribe olanzapine for the treatment of schizophrenia with the expectation of additional therapeutic antipsychotic efficacy relative to other first-line atypical antipsychotics. The goal of this narrative is to revisit the role of oral olanzapine in the management of patients with schizophrenia, including those with recently diagnosed schizophrenia (“first-episode”), those with an established schizophrenia diagnosis who experience acute exacerbations, those receiving long-term antipsychotic treatment as a maintenance intervention, and those with suboptimal response to antipsychotic treatment, including treatment resistance. Collectively, data from published literature support the favorable efficacy of olanzapine compared with other first- and secondgeneration antipsychotics, including lower rates of treatment discontinuation and clinically meaningful improvements in the symptoms of schizophrenia. The development of antipsychotic medications with the favorable efficacy of olanzapine, but with reduced weight gain, could address a major unmet need in the treatment of schizophrenia.

Original languageEnglish (US)
Pages (from-to)2559-2569
Number of pages11
JournalNeuropsychiatric Disease and Treatment
Volume15
DOIs
StatePublished - Jan 1 2019

Fingerprint

olanzapine
Antipsychotic Agents
Schizophrenia
Therapeutics
Weight Gain

Keywords

  • Antipsychotic
  • Efficacy
  • Metabolic dysregulation
  • Weight gain

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

A commentary on the efficacy of olanzapine for the treatment of schizophrenia : The past, present, and future. / Citrome, Leslie; McEvoy, Joseph P.; Todtenkopf, Mark S.; McDonnell, David; Weiden, Peter J.

In: Neuropsychiatric Disease and Treatment, Vol. 15, 01.01.2019, p. 2559-2569.

Research output: Contribution to journalReview article

Citrome, Leslie ; McEvoy, Joseph P. ; Todtenkopf, Mark S. ; McDonnell, David ; Weiden, Peter J. / A commentary on the efficacy of olanzapine for the treatment of schizophrenia : The past, present, and future. In: Neuropsychiatric Disease and Treatment. 2019 ; Vol. 15. pp. 2559-2569.
@article{4096860610a24eb688fc54a6e69b906f,
title = "A commentary on the efficacy of olanzapine for the treatment of schizophrenia: The past, present, and future",
abstract = "Olanzapine is a second-generation atypical antipsychotic with proven efficacy for the treatment of schizophrenia. Approved in 1996, olanzapine is one of the most studied antipsychotics, resulting in a considerable amount of clinical data across diverse patient populations. Despite the fact that olanzapine is associated with a known risk of metabolic side effects, including weight gain, many clinicians continue to prescribe olanzapine for the treatment of schizophrenia with the expectation of additional therapeutic antipsychotic efficacy relative to other first-line atypical antipsychotics. The goal of this narrative is to revisit the role of oral olanzapine in the management of patients with schizophrenia, including those with recently diagnosed schizophrenia (“first-episode”), those with an established schizophrenia diagnosis who experience acute exacerbations, those receiving long-term antipsychotic treatment as a maintenance intervention, and those with suboptimal response to antipsychotic treatment, including treatment resistance. Collectively, data from published literature support the favorable efficacy of olanzapine compared with other first- and secondgeneration antipsychotics, including lower rates of treatment discontinuation and clinically meaningful improvements in the symptoms of schizophrenia. The development of antipsychotic medications with the favorable efficacy of olanzapine, but with reduced weight gain, could address a major unmet need in the treatment of schizophrenia.",
keywords = "Antipsychotic, Efficacy, Metabolic dysregulation, Weight gain",
author = "Leslie Citrome and McEvoy, {Joseph P.} and Todtenkopf, {Mark S.} and David McDonnell and Weiden, {Peter J.}",
year = "2019",
month = "1",
day = "1",
doi = "10.2147/NDT.S209284",
language = "English (US)",
volume = "15",
pages = "2559--2569",
journal = "Neuropsychiatric Disease and Treatment",
issn = "1176-6328",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - A commentary on the efficacy of olanzapine for the treatment of schizophrenia

T2 - The past, present, and future

AU - Citrome, Leslie

AU - McEvoy, Joseph P.

AU - Todtenkopf, Mark S.

AU - McDonnell, David

AU - Weiden, Peter J.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Olanzapine is a second-generation atypical antipsychotic with proven efficacy for the treatment of schizophrenia. Approved in 1996, olanzapine is one of the most studied antipsychotics, resulting in a considerable amount of clinical data across diverse patient populations. Despite the fact that olanzapine is associated with a known risk of metabolic side effects, including weight gain, many clinicians continue to prescribe olanzapine for the treatment of schizophrenia with the expectation of additional therapeutic antipsychotic efficacy relative to other first-line atypical antipsychotics. The goal of this narrative is to revisit the role of oral olanzapine in the management of patients with schizophrenia, including those with recently diagnosed schizophrenia (“first-episode”), those with an established schizophrenia diagnosis who experience acute exacerbations, those receiving long-term antipsychotic treatment as a maintenance intervention, and those with suboptimal response to antipsychotic treatment, including treatment resistance. Collectively, data from published literature support the favorable efficacy of olanzapine compared with other first- and secondgeneration antipsychotics, including lower rates of treatment discontinuation and clinically meaningful improvements in the symptoms of schizophrenia. The development of antipsychotic medications with the favorable efficacy of olanzapine, but with reduced weight gain, could address a major unmet need in the treatment of schizophrenia.

AB - Olanzapine is a second-generation atypical antipsychotic with proven efficacy for the treatment of schizophrenia. Approved in 1996, olanzapine is one of the most studied antipsychotics, resulting in a considerable amount of clinical data across diverse patient populations. Despite the fact that olanzapine is associated with a known risk of metabolic side effects, including weight gain, many clinicians continue to prescribe olanzapine for the treatment of schizophrenia with the expectation of additional therapeutic antipsychotic efficacy relative to other first-line atypical antipsychotics. The goal of this narrative is to revisit the role of oral olanzapine in the management of patients with schizophrenia, including those with recently diagnosed schizophrenia (“first-episode”), those with an established schizophrenia diagnosis who experience acute exacerbations, those receiving long-term antipsychotic treatment as a maintenance intervention, and those with suboptimal response to antipsychotic treatment, including treatment resistance. Collectively, data from published literature support the favorable efficacy of olanzapine compared with other first- and secondgeneration antipsychotics, including lower rates of treatment discontinuation and clinically meaningful improvements in the symptoms of schizophrenia. The development of antipsychotic medications with the favorable efficacy of olanzapine, but with reduced weight gain, could address a major unmet need in the treatment of schizophrenia.

KW - Antipsychotic

KW - Efficacy

KW - Metabolic dysregulation

KW - Weight gain

UR - http://www.scopus.com/inward/record.url?scp=85073379762&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073379762&partnerID=8YFLogxK

U2 - 10.2147/NDT.S209284

DO - 10.2147/NDT.S209284

M3 - Review article

AN - SCOPUS:85073379762

VL - 15

SP - 2559

EP - 2569

JO - Neuropsychiatric Disease and Treatment

JF - Neuropsychiatric Disease and Treatment

SN - 1176-6328

ER -